We observed that combined treatment of TMZ with an eEF-2 kinase-targeted siRNA (Figure 1A) or the eEF-2 kinase inhibitor NH125 (0.5μM) (Figure 1B) significantly increased the growth-inhibitory effect of TMZ on the human glioma cell lines LN229 and U251, as compared with treatment with TMZ alone. Here, EEF2K is linked to central nervous system cancer.